Nexara Health — Health Canada Drug Establishment Licence #3-002896

DIANE-35 2 MG

Last verified 2026-09-08 · Source: Health Canada Drug Product Database (DPD), DIN 02233542

DIANE-35 2 MG

CYPROTERONE ACETATE : 2 MG ETHINYL ESTRADIOL : 35 MCG · DIN 02233542 · BAYER INC

Health Canada status: MARKETED

What is DIANE-35?

DIANE-35 2 MG contains CYPROTERONE ACETATE : 2 MG ETHINYL ESTRADIOL : 35 MCG. It is listed in the Health Canada Drug Product Database under DIN 02233542, held by BAYER INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Dec-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is DIANE-35 used for?

Treatment of women with severe acne, with associated symptoms of androgenization (seborrhea, mild hirsutism), unresponsive to topical therapy and oral antibiotics.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02233542
Brand nameDIANE-35
Generic / active ingredientCYPROTERONE ACETATE : 2 MG ETHINYL ESTRADIOL : 35 MCG
ManufacturerBAYER INC
Strength2 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeG03HB01 CYPROTERONE AND ESTROGEN
AHFS class92:92.00
BiosimilarNo
Health Canada statusMARKETED
Status date17-Dec-2007
Original market date1998-04-08 00:00:00

How is it administered?

Taken orally. Should be discontinued 3 to 4 cycles after signs have completely resolved. Not for contraception alone.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly detailed in provided text (refers to Storage and Stability section).

How is it supplied?

Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section).

Contraindications

History of thromboembolic disorders, cerebrovascular/coronary artery disease, active liver disease, liver tumours, breast/estrogen-dependent cancer, undiagnosed vaginal bleeding, pregnancy.

Warnings and precautions

Increased risk of venous thromboembolism (VTE). Smoking increases cardiovascular risk. Discontinue if thromboembolic symptoms, jaundice, or severe headaches occur.

What can be used instead?

Other Canadian products sharing ATC code G03HB01 CYPROTERONE AND ESTROGEN. 5 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
CLÉO -350.035 MGTABLETALTIUS HEALTHCARE INCMARKETEDDIN 02436736
CYESTRA-350.035 MGTABLETENDO OPERATIONS LTD.MARKETEDDIN 02290308
TARO-CYPROTERONE/ETHINYL ESTRADIOL2 MGTABLETSUN PHARMA CANADA INCMARKETEDDIN 02425017
TEVA-CYPROTERONE / ETHINYL ESTRADIOL2 MGTABLETTEVA CANADA LIMITEDMARKETEDDIN 02309556
MYLAN-CYPROTERONE / ETHINYLESTRADIOL2 MGTABLETMYLAN PHARMACEUTICALS ULCCANCELLED PRE MARKETDIN 02491257

Who else supplies CYPROTERONE AND ESTROGEN worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. CYPROTERONE AND ESTROGEN appears in 75 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for DIANE-35

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Related pages

Sourcing this product